{
  "source": "PA-Med-Nec-Vtama.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2286-5\nProgram Prior Authorization/Medical Necessity\nMedication Vtama® (tapinarof)\nP&T Approval Date 9/2022, 11/2022, 11/2023, 12/2024, 5/2025\nEffective Date 8/1/2025\n1. Background:\nVtama cream is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque\npsoriasis in adults and the topical treatment of atopic dermatitis in adults and pediatric patients 2\nyears of age and older.1\n2. Coverage Criteriaa:\nA. Plaque Psoriasis\n1. Initial Authorization\na. Vtama will be approved based on all of the following criteria:\n(1) Diagnosis of plaque psoriasis\n-AND-\n(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance\nto one of the following topical therapies2:\n(a) Corticosteroids (e.g., betamethasone, clobetasol, desonide)\n(b) Vitamin D analogs (e.g., calcitriol, calcipotriene)\n(c) Tazarotene\n(d) Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)\n(e) Anthralin\n(f) Coal tar\n-AND-\n(3) Patient is not receiving Vtama in combination with a Targeted Immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),\nIlumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2025 UnitedHealthcare Services, Inc.\n1\na. Vtama will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to therapy\n-AND-\n(2) Patient is not receiving Vtama in combination with a Targeted Immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodaluma",
    " (certolizumab), Simponi (golimumab), Orencia\n(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),\nIlumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\nB. Atopic Dermatitis\n1. Initial Authorization\na. Vtama will be approved based on all of the following criteria:\n(1) Diagnosis of atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to one of the following\ntherapeutic classes of topical therapies:\n(a) One of the following:\nFor mild atopic dermatitis: a topical corticosteroid [e.g., DesOwen\no\n(desonide), hydrocortisone] (any potency)\nFor moderate atopic dermatitis: a topical corticosteroid of at least a\no\nmedium- to high-potency (e.g., Elocon (mometasone furoate),\nSynalar (fluocinolone acetonide), Lidex (fluocinonide)]\n(b) One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)]*\n-AND-\n(3) Patient is not receiving Vtama in combination with a targeted immunomodulator\n[e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Vtama will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to therapy\n© 2025 UnitedHealthcare Services, Inc.\n2\n-AND-\n(2) Patient is not receiving Vtama in combination with a targeted immunomodulator\n[e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab),\nRinvoq (upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Elidel and Protopic/tacrolimus ointment require prior authorization.\n3. Additio",
    "benefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n* Elidel and Protopic/tacrolimus ointment require prior authorization.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Vtama [package insert]. Long Beach, CA: Dermavant Sciences Inc.; December 2024.\n2. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the\nmanagement and treatment of psoriasis with topical therapy and alternative medicine\nmodalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.\nProgram Prior Authorization/Medical Necessity - Vtama® (tapinarof)\nChange Control\n9/2022 New program.\n11/2022 Revised trial and failure requirement from either two topical therapies\nor calcipotriene and betamethasone dipropionate to a trial and failure of\none topical therapy.\n11/2023 Annual review. Updated not to be used in combination to Targeted\nImmunomodulators. Simplified reauthorization criteria to only require\npositive clinical response and not used in combination with other\ntreatment medications.\n12/2024 Annual review. Removed prescriber requirement. Updated initial\nauthorization to 12 months.\n5/2025 Added coverage criteria for atopic dermatitis. Updated background and\nreference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}